Establishment Labs Holdings Inc (ESTA) Stock Price & How to Invest

Establishment Labs designs and manufactures silicone breast implants and related devices under the Motiva brand, made at two company-owned plants in Costa Rica and sold in roughly 85 countries. The core product is a family of implants built around SmoothSilk, a proprietary nanotextured shell surface intended to reduce friction and bacterial attachment and, by extension, the rate of capsular contracture. Around that implant the company has built a set of procedures rather than just a product line: Mia Femtech, a minimally invasive breast harmonization procedure done under local anesthesia with no visible breast scar, and Preservé, a tissue-preserving minimally invasive approach for primary augmentation and mastopexy augmentation that works across a wider range of cases and larger sizes. Motiva Flora, a tissue expander with an integrated radio-frequency port for post-mastectomy reconstruction, extends the same platform into the reconstructive market. More than five million Motiva devices have been placed globally since launch.

The investment picture turns almost entirely on the United States. Motiva received FDA premarket approval in September 2024, the first new breast implant approved in the US since 2013, into a market long split between Allergan's Natrelle and Johnson & Johnson's Mentor. That approval is what changed the growth arithmetic: Motiva USA revenue reached about $24.7 million in the second quarter of 2026, roughly 141% higher than a year earlier, and pulled total revenue to $67.5 million, up 31.7%. Because US and minimally invasive sales carry richer economics, gross margin lifted to about 70.6% and adjusted EBITDA turned positive at roughly $3.7 million, a third consecutive positive quarter. What has not turned yet is GAAP profit or free cash flow. The company lost about $11.7 million in the quarter, carries roughly $264 million of debt against about $71 million of cash after a $300 million Oaktree refinancing that pushes maturity to 2031, and burned about $20.9 million of operating cash in the first half. Management has guided full-year 2026 revenue to $269 million to $271 million and expects free cash flow to turn positive in the second half. Shares fell about 13% on the August 6, 2026 print despite the revenue beat and guidance raise, because the per-share loss came in wider than expected, which is a fair preview of how this stock behaves.

The balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow. Interest expense of about $7.0 million a quarter is now larger than adjusted EBITDA, so the path to GAAP profit depends on continued volume growth rather than on cost cuts. Demand is discretionary and cash-pay: breast augmentation is elective and consumer-financed, which historically makes procedure volumes sensitive to consumer confidence and credit conditions, and the company has already seen weakness in individual markets including China. Competitive response is unpriced, since AbbVie and Johnson & Johnson are vastly larger and can meet a share threat with price or bundling. The company also carries a credibility overhang from an October 2022 Hindenburg Research report questioning conflicts of interest in its safety studies, which triggered multiple law-firm investigations at the time, and separate accounting-focused allegations in 2019. Finally, the stock is thinly capitalized relative to its multiple, with about 29 million shares outstanding, and it has moved more than 10% in a single session on earnings.

9 analysts publish price targets on ESTA, averaging $97.22 against a $79.05 price as of August 2026, or +23.0%. The published targets run from $84.00 to $117.00, a moderate spread, and the ratings split 8 buy, 1 hold, 0 sell. Over the last six months there have been 9 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ESTA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Establishment Labs Holdings Inc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. United States share gain against a two-brand incumbency. The US aesthetic breast market has been effectively a duopoly between Allergan's Natrelle and Mentor for over a decade, and Motiva is the first new entrant to clear the FDA since 2013. The most optimistic published target, $117.00, assumes this works close to its best case.

The case against. The balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow. The most pessimistic target, $84.00, is roughly what ESTA is worth if this bites instead.

Read the full bull and bear case on ESTA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Establishment Labs Holdings Inc's investor relations page or your broker.

• Revenue (TTM): ~$246 million, up ~39% year over year
• Q2 2026 revenue: ~$67.5 million, up ~31.7%, with Motiva USA at ~$24.7 million
• Gross margin / adjusted EBITDA: ~70.6% gross margin, adjusted EBITDA ~$3.7 million (third straight positive quarter)
• GAAP net loss: ~$11.7 million in Q2 2026 (~$0.39 a share), ~$38.9 million over the trailing twelve months
• Cash vs debt: ~$71 million cash against ~$264 million of debt, refinanced with Oaktree to 2031
• Market cap / price to sales: ~$2.3 billion at ~$79 a share, roughly 9x trailing sales

There is no meaningful earnings multiple here because there are no earnings, so the stock is valued on sales and on the credibility of the US ramp. At roughly 9 times trailing revenue, ESTA prices at a premium to most profitable medtech peers, which is the market's way of paying forward for a company growing above 30% with gross margins above 70%. Full-year 2026 guidance of $269 million to $271 million implies roughly 28% growth, and the sell side has clustered targets between about $76 and $117, a wide band that reflects genuine disagreement about how fast a duopoly cracks.

Other names that sit close to ESTA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ESTA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ESTA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ESTA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Establishment Labs is a genuine share-gain story in a duopoly market, priced at roughly 9 times sales for a company that has only just reached positive adjusted EBITDA and still runs a leveraged balance sheet.

Whether ESTA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ESTA a buy or a sell?, and where the stock could go from here in the ESTA stock forecast.

For income investors, whether ESTA pays a dividend and how the payout looks is covered in does ESTA pay a dividend? And to weigh ESTA against a peer, read the full side-by-side comparisons: ESTA vs ABBV and ESTA vs JNJ.